BioSelective Capital Investments

Overview

BioSelective Capital Investments is a risk-capital investment firm based in Park City, Utah, focusing on the biopharmaceutical sector. The firm specializes in private equity and venture capital investments, targeting companies at various stages, including seed, early-stage, Series A, Series B, growth, late-stage, pre-IPO, buyout, turnaround, and distressed situations. Their geographical focus is primarily within the United States, and they invest in industries such as biotechnology, pharmaceuticals, and diagnostics. BioSelective Capital Investments has a history of strategic acquisitions, including the formation of Forma Life Sciences, Inc. through the acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, in February 2026. This acquisition expanded their portfolio in the pharmaceutical manufacturing sector. The firm's investment approach emphasizes value creation through sustainable revenue growth, profit maximization, and cost containment, leveraging their deep knowledge and competitive edge in biopharma and diagnostics. They prioritize investments where they can serve as operating partners, actively contributing to the success of their portfolio companies. BioSelective Capital Investments is led by Chairman and Managing Partner Cyrus K. Mirsaidi, who brings extensive experience in strategic alliances, business planning, and management development to the firm. Under his leadership, the firm continues to focus on building culturally diverse teams and establishing well-defined, measurable goals to drive success in their investments. Their investment philosophy is rooted in a deep and genuine regard for the teams that make up their portfolio companies, applying the principle that 'fish stinks from the head' by investing in people, especially the CEO, first and foremost. This approach reflects their commitment to fostering strong leadership and operational excellence within their portfolio. BioSelective Capital Investments remains dedicated to identifying and supporting innovative companies in the biopharmaceutical sector, aiming to bring transformative therapies to market and improve patient outcomes. Through strategic investments and active partnership, BioSelective Capital Investments continues to play a significant role in advancing the biopharmaceutical industry, contributing to the development of novel medical treatments and supporting the growth of companies that are at the forefront of healthcare innovation.

Portfolio Companies